Comparative evaluation of copeptin and NT‑proBNP in patients with severe acute decompensated heart failure, and prediction of adverse events in a 90‑day follow‑up period: A prospective clinical observation trial

  • Authors:
    • Jun Jia
    • Guang‑Lei Chang
    • Shu Qin
    • Jia Chen
    • Wen‑Yan He
    • Kai Lu
    • Yong Li
    • Dong‑Ying Zhang
  • View Affiliations

  • Published online on: February 8, 2017     https://doi.org/10.3892/etm.2017.4111
  • Pages: 1554-1560
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study compared the prognostic value of a marker, the C‑terminal section of the arginine vasopressin prohormone (copeptin), with N‑terminal B‑type natriuretic peptide (NT‑proBNP) in patients with severe acute decompensated heart failure. A prospective, observational cohort study was conducted in a tertiary care hospital and enrolled 129 patients with severe acute decompensated heart failure. Clinicians were blinded to investigational markers except NT‑proBNP, and the study participants were followed up for 90 days. The end-point was a composite of cardiovascular death or re‑hospitalization due to decompensated heart failure. Of the 129 patients enrolled, 47 reached the end-point and 82 were in a stable condition during follow‑up. Receiver operating characteristic curve analysis revealed that the areas under curve for the prediction of adverse events within 90 days were similar for copeptin [0.602±0.052; 95% confidence interval (CI), 0.499‑0.705], NT‑proBNP (0.659±0.048; 95% CI, 0.565‑0.753) and their combination (0.670±0.050; 95% CI, 0.573‑0.767). Kaplan‑Meier survival analysis showed that the predictive value of NT‑proBNP regarding the probability of survival was superior compared with that of copeptin (log‑rank test for trend, P=0.001 vs. 0.040). Furthermore, multivariate Cox proportional‑hazards regression analysis revealed that increased NT‑proBNP and copeptin plasma concentrations were significant independent predictors of adverse events. The present study provided evidence that copeptin has similar predictive properties compared with NT‑proBNP regarding adverse events within 90‑days in patients with severe acute decompensated heart failure, but that copeptin may not provide superior 90‑day prediction compared to NT‑proBNP.
View Figures
View References

Related Articles

Journal Cover

April-2017
Volume 13 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Jia J, Chang GL, Qin S, Chen J, He WY, Lu K, Li Y and Zhang DY: Comparative evaluation of copeptin and NT‑proBNP in patients with severe acute decompensated heart failure, and prediction of adverse events in a 90‑day follow‑up period: A prospective clinical observation trial. Exp Ther Med 13: 1554-1560, 2017
APA
Jia, J., Chang, G., Qin, S., Chen, J., He, W., Lu, K. ... Zhang, D. (2017). Comparative evaluation of copeptin and NT‑proBNP in patients with severe acute decompensated heart failure, and prediction of adverse events in a 90‑day follow‑up period: A prospective clinical observation trial. Experimental and Therapeutic Medicine, 13, 1554-1560. https://doi.org/10.3892/etm.2017.4111
MLA
Jia, J., Chang, G., Qin, S., Chen, J., He, W., Lu, K., Li, Y., Zhang, D."Comparative evaluation of copeptin and NT‑proBNP in patients with severe acute decompensated heart failure, and prediction of adverse events in a 90‑day follow‑up period: A prospective clinical observation trial". Experimental and Therapeutic Medicine 13.4 (2017): 1554-1560.
Chicago
Jia, J., Chang, G., Qin, S., Chen, J., He, W., Lu, K., Li, Y., Zhang, D."Comparative evaluation of copeptin and NT‑proBNP in patients with severe acute decompensated heart failure, and prediction of adverse events in a 90‑day follow‑up period: A prospective clinical observation trial". Experimental and Therapeutic Medicine 13, no. 4 (2017): 1554-1560. https://doi.org/10.3892/etm.2017.4111